Iovance Biotherapeutics, Inc. (IOVA)
14.22
-0.02
(-0.11%)
USD |
NASDAQ |
Oct 02, 16:00
14.22
+0.01
(+0.07%)
After-Hours: 20:00
Iovance Biotherapeutics Net Income (Quarterly) : -47.32M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -47.32M |
| March 31, 2026 | -79.04M |
| December 31, 2025 | -71.90M |
| September 30, 2025 | -91.25M |
| June 30, 2025 | -111.66M |
| March 31, 2025 | -116.16M |
| December 31, 2024 | -78.56M |
| September 30, 2024 | -83.54M |
| June 30, 2024 | -97.10M |
| March 31, 2024 | -112.98M |
| December 31, 2023 | -116.38M |
| September 30, 2023 | -113.76M |
| June 30, 2023 | -106.53M |
| March 31, 2023 | -107.37M |
| December 31, 2022 | -105.32M |
| September 30, 2022 | -99.62M |
| June 30, 2022 | -99.35M |
| March 31, 2022 | -91.61M |
| December 31, 2021 | -99.33M |
| September 30, 2021 | -86.12M |
| June 30, 2021 | -81.35M |
| March 31, 2021 | -75.45M |
| December 31, 2020 | -68.40M |
| September 30, 2020 | -58.57M |
| June 30, 2020 | -63.02M |
| Date | Value |
|---|---|
| March 31, 2020 | -69.60M |
| December 31, 2019 | -63.57M |
| September 30, 2019 | -49.49M |
| June 30, 2019 | -47.55M |
| March 31, 2019 | -36.95M |
| December 31, 2018 | -32.58M |
| September 30, 2018 | -33.83M |
| June 30, 2018 | -30.66M |
| March 31, 2018 | -26.52M |
| December 31, 2017 | -25.85M |
| September 30, 2017 | -22.15M |
| June 30, 2017 | -23.38M |
| March 31, 2017 | -20.68M |
| December 31, 2016 | -15.69M |
| September 30, 2016 | -18.76M |
| June 30, 2016 | -11.56M |
| March 31, 2016 | -6.884M |
| December 31, 2015 | -8.956M |
| September 30, 2015 | -7.635M |
| June 30, 2015 | -6.368M |
| March 31, 2015 | -5.298M |
| December 31, 2014 | -4.867M |
| September 30, 2014 | -2.798M |
| June 30, 2014 | -2.110M |
| March 31, 2014 | -2.260M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AVITA Medical, Inc. | -7.663M |
| Amgen, Inc. | 2.375B |
| Halozyme Therapeutics, Inc. | 229.91M |
| Neurocrine Biosciences, Inc. | 144.40M |
| Editas Medicine, Inc. | -18.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 99.31M |
| Total Expenses (Quarterly) | 146.63M |
| EPS Diluted (Quarterly) | -0.1051 |
| Enterprise Value | 6.187B |
| Gross Profit Margin (Quarterly) | 46.54% |
| Profit Margin (Quarterly) | -47.64% |
| Earnings Yield | -5.07% |
| Normalized Earnings Yield | -5.005 |